DNMT3A and acute myeloid leukemia: IDH1/2 mutations, though, seem different: in a study performed on 31 NPM1-mutated AML patients that analyzed together DNMT3A and IDH1/2 mutations, the latter proved highly correlated with NPM1 (r = 0.6818, p < 0.0001), and highly predictive for clinical relapse [55].